Health News Review
  • Jan 25 2013

    Ghostwriting part 3: psych drug Paxil – and conclusion

    The GlaxoSmithKline psychiatric drug Paxil is the topic of the third and final part of a series of unsolicited guest blog submissions by Jonathan Leo, PhD, and Jeffrey Lacasse, PhD. ——————————— Paxil, GlaxoSmithKline, and the University of Pennsylvania In June of 2012 charges of ghostwriting were made by a University of Pennsylvania Professor over a [...]

    4 Comments
  • Jan 24 2013

    Ghostwriting series part 2: Medtronic’s InFuse spinal fusion surgery product

    In the second part of their 3-part guest blog series on ghostwriting of medical papers, researchers Jonathan Leo, PhD, and Jeffrey Lacasse, PhD address “Medtronics, InFuse and the University of Wisconsin.” —————————————– InFuse, manufactured by Medtronic and approved by the FDA in 2002, is used for promoting the growth of bone graft material during surgery.  [...]

    1 Comment
  • Jan 11 2013

    Yale’s Harlan Krumholz: 5 Things You Should Know On The Myth Of Tamiflu

    Have you ever tried having a discussion of the evidence for Tamiflu with your doctor? (A physician-reader of our work has reminded me to use generic names whenever possible.  The generic name for Tamiflu is oseltamivir.) Is this one of the top medical marketing success stories after, say, Lamisil (terbinafine) for toenail fungus? On Forbes.com, [...]

    No Comments
  • Dec 14 2012

    New word of the week: 23andMe aims to valorize your spit

    The following is a guest post by Alan Cassels, a drug policy researcher at the University of Victoria.  Alan was founder of Media Doctor Canada, a project very similar to our HealthNewsReview.org, but a project that is unfortunately on the shelf for now. ————————————————- Life might be looking up for 23andMe, the world’s largest dataset [...]

    1 Comment
  • Nov 20 2012

    RxISK.org — A Megaphone For Patients and Their Doctors

    Noteworthy new website launch – RxISK.org: “Making medicines safer for all of us.” It’s founded by Dr. David Healy, internationally renowned psychiatrist and author from Wales; Dr. Dee Mangin of New Zealand, Dr. Kalman Applbaum of the University of Wisconsin, Dr. Nancy Olivieri and others you can read about here. The project’s own description: “RxISK [...]

    No Comments
  • Nov 16 2012

    Up the nose…in the armpit…what else can you do with testosterone?

    Putting the update at the top:  hours after posting this, I’ve now been told there are, indeed, anal testosterone suppositories. Thanks to Leonore Tiefer for this tip: The newest “female sexual dysfunction drug” hitting the PR waves is a nasal testosterone gel in clinical trials in the US, Canada and Australia. The Dinah Project website [...]

    No Comments
  • Nov 14 2012

    “Softening the beaches before amphibious assault with a new drug”

    On Twitter, that’s how Alan Cassels – drug policy researcher at the University of Victoria, British Columbia – referred to the Wall Street Journal’s reporting in this column, “Emerging Type of Heartburn Defies Drugs, Diagnosis.” And I see what he means. First, the column sets you up with the numbers game: Some 44% of Americans [...]

    2 Comments
  • Oct 31 2012

    More Pfizer Pfun

    The Alt_Mentalities website published a piece, “Lemons into Lemonade: How an off-label marketing fine can be good for business,” tracking Pfizer’s journey through fines for off-label marketing of Neurontin and, later, for Lyrica and other drugs. Punchline question in the piece: “Was taking the hit for off-label marketing in 2004 all part of a plan to boost [...]

    No Comments
  • Oct 31 2012

    BMJ pushes Roche for raw data on Tamiflu trials

    BMJ journal editor Fiona Godlee this week published an open letter to Roche, makers of the flu drug Tamiflu. Background provided by BMJ: Roche promised in 2009 to release full reports from clinical trials of oseltamivir in response to an investigation by the BMJ and the Cochrane Collaboration. In this open letter to John Bell, [...]

    No Comments
  • Jul 17 2012

    Pill progress: what are the odds a drug makes it to market?

    The following is a guest post by Chad Parmet, a Research Associate with the Informed Medical Decisions Foundation.  Chad gathers, evaluates and summarizes current medical research in support of new or revised Shared Decision-Making® programs. Before joining the Foundation, he worked as a medical writer. He holds a BA in physics from the University of [...]

    3 Comments 1 Star